Clinical trials
Myelofibrosis clinical trials
Below are recruiting myelofibrosis clinical trials, each written for real people, not researchers. We’re tracking 88 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07521046RecruitingPhase 1
Adding interferon to ruxolitinib for myelofibrosis
This trial tests whether adding a drug called interferon alfa-2b to the standard treatment ruxolitinib can help people with myelofibrosis. It may reduce spleen size and improve blood counts.
Salt Lake City, UtahAges 18 years+ - NCT07394153RecruitingPhase 2
Testing pacritinib for myelofibrosis patients with low platelets
This trial tests if pacritinib, a JAK inhibitor, can help people with myelofibrosis who also have low platelet counts. It may be an option for those who haven't had JAK inhibitor therapy before or who didn't respond to a previous one.
Barcelona, BarcelonaAges 18 years+ - NCT06151119Recruiting
PET scan test for myelofibrosis using a special tracer
This study uses a new type of PET/CT scan with a tracer called 68Ga-FAPI to help diagnose myelofibrosis, see how advanced it is, and check if treatment is working. It may help doctors better understand your condition and plan your care.
Xiamen, FujianAges 18 years+ - NCT07379125RecruitingPhase 1
Study of PMD-026 for worsening myelofibrosis
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
St Louis, MissouriAges 18 years+ - NCT06605586RecruitingPhase 1/Phase 2
Test of tasquinimod for myelofibrosis that stopped responding to JAK inhibitor therapy
This trial tests an oral drug called tasquinimod for people with myelofibrosis that no longer responds to or cannot take a JAK inhibitor. The goal is to see if tasquinimod can help shrink an enlarged spleen and improve symptoms.
AachenAges 18 years+ - NCT07250646RecruitingPhase 1
Rebecsinib for secondary AML or high-risk myelofibrosis
This trial tests a new drug called rebecsinib for people with a certain type of leukemia (secondary acute myeloid leukemia) or a high-risk bone marrow disorder (myelofibrosis) that has come back or not responded to other treatments. The goal is to see if it works and is safe.
Duarte, CaliforniaAges 18 years+ - NCT06896344Recruiting
How cell particles affect blood stem cells in myelofibrosis
This trial is looking at whether tiny particles released by certain cells from people with myelofibrosis can affect their blood-forming stem cells. The goal is to understand the disease better and find new treatments.
Pavia, PaviaAges 18 years+ - NCT07128381RecruitingPhase 1/Phase 2
Axatilimab plus Ruxolitinib for Myelofibrosis and CMML
This trial tests a new combination of two drugs (axatilimab and ruxolitinib) for people with myelofibrosis or a related blood cancer called CMML. The goal is to see if the combination works better than standard treatments for these diseases.
Houston, TexasAges 18 years+ - NCT07104799RecruitingPhase 1
Momelotinib before and after stem cell transplant for myelofibrosis
This trial tests whether the drug momelotinib, given before and after a stem cell transplant (also called a bone marrow transplant), can help people with myelofibrosis. The hope is that it will make the transplant safer and more effective.
Boston, MassachusettsAges 18 years+ - NCT06887803RecruitingPhase 1/Phase 2
Roginolisib plus ruxolitinib for myelofibrosis not helped by JAK inhibitors
This trial tests a new combination of two drugs, roginolisib and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough with ruxolitinib alone. It aims to see if adding roginolisib can improve symptoms and spleen size.
Florence, FlorenceAges 18 years+ - NCT06781099Recruiting
Iron removal machine for MDS or myelofibrosis with high iron
This trial tests a new way to remove extra iron from the blood using a machine (like dialysis). It is for people with myelodysplastic syndrome or myelofibrosis who have severe anemia, high iron levels, and cannot take standard iron-removal pills or injections.
Oullins-Pierre-BéniteAges 18 years+ - NCT06773195RecruitingPhase 1/Phase 2
Study of Ruxolitinib and Ulixertinib for Myelofibrosis
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
Boston, MassachusettsAges 18 years+ - NCT06712810RecruitingPhase 1
Q702 for blood cancers and histiocytic disorders
This study tests an experimental pill called Q702 for people with certain blood cancers and related disorders (like histiocytoses, myelofibrosis, and lymphomas) that have not responded to standard treatments. It aims to see if Q702 is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT06674382Recruiting
Half-matched stem cell transplant for myelofibrosis
This trial tests whether a stem cell transplant from a half-matched (haploidentical) donor can help people with myelofibrosis. You might join if you don't have a fully matched sibling or unrelated donor.
BeijingAges Any age - NCT06661915RecruitingPhase 2
Combination treatment for advanced myeloproliferative neoplasms
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
Irvine, CaliforniaAges 18 years+ - NCT06533813Recruiting
Studying health outcomes in people with myelofibrosis
This study collects information from people diagnosed with myelofibrosis to understand how the disease affects them over time. It may help researchers learn more about the condition and improve future care.
YerevanAges 18–100 - NCT06414681RecruitingEarly Phase 1
Tagraxofusp and pacritinib for myelofibrosis after JAK inhibitor
This study tests a new combination of two drugs, tagraxofusp and pacritinib, for people with myelofibrosis who have already tried a JAK inhibitor without enough benefit or who couldn't take one. The goal is to see if the combination can shrink the spleen and improve symptoms.
Fairway, KansasAges 18 years+ - NCT06345495RecruitingPhase 2
High-dose ruxolitinib and stem cell transplant for enlarged spleen in myelofibrosis
This trial tests a higher dose of ruxolitinib before a stem cell transplant for people with myelofibrosis who have an enlarged spleen. It aims to see if this approach helps the transplant work better.
Houston, TexasAges 18–75 - NCT06164561Recruiting
FAPI PET/MRI scan for myelofibrosis
This trial tests whether a special type of PET scan (using a tracer called 18F-FAPI) can see myelofibrosis activity better than standard scans. It may help doctors track the disease more accurately without needing extra biopsies.
Hangzhou, ZhejiangAges 18–80 - NCT06122831RecruitingPhase 1/Phase 2
TQ05105 and TQB3617 for myelofibrosis
This trial tests a combination of two oral medications for people with myelofibrosis, a type of bone marrow cancer. It may be an option if you have not been helped by standard JAK inhibitor therapy or if you have never tried one.
Guangzhou, GuangdongAges 18 years+ - NCT05980806RecruitingPhase 2
Selinexor for myelofibrosis with low platelets (no prior JAK inhibitors)
This trial tests a drug called selinexor (taken by mouth) for people with myelofibrosis who have low to moderate platelet counts and haven't tried JAK inhibitors yet. It aims to shrink the spleen and improve symptoms.
Duarte, CaliforniaAges 18 years+ - NCT05710211Recruiting
Study of gene changes in ASXL1-mutated myelofibrosis
This study looks at how ASXL1 gene changes shape myelofibrosis over time. It may help doctors better understand the disease and potentially improve future treatments.
AngersAges 18 years+ - NCT05714072RecruitingPhase 1
Ruxolitinib plus abemaciclib for myelofibrosis after ruxolitinib
This trial tests whether adding abemaciclib to ongoing ruxolitinib can better control myelofibrosis in people who are not getting enough benefit from ruxolitinib alone. It is designed to see safety and response in a specific group with intermediate-2 or high-risk disease and ongoing symptoms or enlarged spleen.
Basking Ridge, New JerseyAges 18 years+ - NCT05535764RecruitingPhase 1
Test PegINFa after bone marrow transplant for myelofibrosis
This Phase 1 study tests PegINFa (after a bone marrow transplant) to see if it is safe and can help control myelofibrosis. You must be eligible for transplant and meet specific donor, timing, and health criteria before starting the study drug.
Salt Lake City, UtahAges 18 years+
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myelofibrosis?
- Yes. Clin2 currently lists 88 recruiting myelofibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myelofibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myelofibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.